Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The immunobiology of systemic sclerosis.Semin Arthritis Rheum. 2008; 38: 132-160
- Gastrointestinal motility disorders in scleroderma. Review.Arthritis Rheum. 1994; 37: 1265-1282
- Gastric and enteric involvement in progressive systemic sclerosis.J Clin Gastroenterol. 2008; 42: 5-12
- Prevalence and severity of depression and anxiety in patients with systemic sclerosis: an epidemiologic survey and investigation of clinical correlates.J Clin Rheumatol. 2017; 23: 80-86
- Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Research Support, N.I.H., Extramural.Rheumatology. 2011; 50: 330-334
- Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey.Elsevier, 2016: 115-123
- Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study.Eur J Gastroenterol Hepatol. 2009; 21: 176-182
- Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort.Elsevier, 2011: 38-47
- Fatigue in systemic sclerosis: a systematic review. Systematic Review.Clin Exp Rheumatol. 2018; 36: 150-160
- The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality.Dis Esophagus. 2019; 32: doy136
- Severe organ involvement in systemic sclerosis with diffuse scleroderma.Arthritis Rheum. 2000; 43: 2437-2444
- Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.Journal of Scleroderma and Related Disorders. 2019; 6: 37-43
- Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.Rheumatology. 2019; 58: 636-644
- Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis.Clin Exp Rheumatol. 2021; 39: S142-S148
- Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.Rheumatology. 2016; 55: 115-119
- Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.Am J Physiol Gastrointest Liver Physiol. 2016; 310: G1052-G1060
- Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.Clin Rheumatol. 2018; 37: 1239-1247
- Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with high resolution manometry.Clin Exp Rheumatol. 2016; 34: 63-69
- Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre.Ann Rheum Dis. 2015; 74: 124-128
- pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.Aliment Pharmacol Ther. 2017; 45: 883-898
- Gastrointestinal manifestations of systemic sclerosis.Rheumatology. 2018; 8: 235
- Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls.Am J Med. 1969; 46: 428-440
- Antibody-mediated gastrointestinal dysmotility in scleroderma.Gastroenterology. 2002; 123: 1144-1150
- Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.Ann Rheum Dis. 2009; 68: 710
- Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.Clin Rheumatol. 2020; https://doi.org/10.1007/s10067-020-05479-5
- Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.Am J Physiol Gastrointest Liver Physiol. 2009; 297: G1206-G1213
- Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies.Arthritis Res Ther. 2020; 22: 32
- Ganglionic acetylcholine receptor antibodies and autonomic dysfunction in autoimmune rheumatic diseases.Int J Mol Sci. 2020; 21: 1332
- Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. Multicenter Study Research Support, Non-U.S. Gov't.Alimentary Pharmacology & Therapeutics. 2014; 40: 189-199
- A case–control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).Gut. 2006; 55: 1697-1703
- Reliability, validity, and minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract (UCLA SCTC 2.0) instrument.Arthritis Rheum. 2009; 10: 603
- Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.Am J Gastroenterol. 2014; 109: 1804-1814
- Construct validity of the patient-reported outcomes measurement information system gastrointestinal symptom scales in systemic sclerosis.Arthritis Care Res. 2014; 66: 1725-1730
- Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Validation Study.Ann Rheum Dis. 2007; 66: 1651-1655
- Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2013; 37: 564-572
- GERD questionnaire for diagnosis of gastroesophageal reflux disease in systemic sclerosis.Clin Exp Rheumatol. 2014; 32: 98-102
- Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders.Qual Life Res. 2004; 13: 1737-1749
- Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD).Eur J Surg Suppl. 1998; : 41-49
- Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. Research Support, Non-U.S. Gov't.J Rheumatol. 2019; 46: 78-84
- Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.Qual Life Res. 2004; 13: 1751-1762
- Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Multicenter Study Validation Study.Rheumatology. 2017; 56: 1302-1311
- Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.Arthritis Res Ther. 2021; 23: 1-11
- Orofacial manifestations of systemic sclerosis.Br Dent J. 2016; 221: 305-310
- Systemic sclerosis–associated Sjögren's syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients.Arthritis Rheum. 2006; 54: 2243-2249
- Orofacial consequences of systemic sclerosis: A systematic review.Journal of Scleroderma and Related Disorders. 2018; 3: 81-90
- Validity and reliability of the Mouth Handicap of Systemic Sclerosis questionnaire in a UK population.J Oral Pathol Med. 2020; 49: 986-993
- Sjögren's syndrome is associated with and not secondary to systemic sclerosis.Rheumatology. 2007; 46: 321-326
- Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study.Int J Mol Sci. 2016; 17: 1189
- The spectrum of orofacial manifestations in systemic sclerosis: a challenging management.Oral Dis. 2017; 23: 424-439
- Treatment of primary Sjögren syndrome: a systematic review.JAMA. 2010; 304: 452-460
- Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial.Arch Intern Med. 1999; 159: 174-181
- Recommendations for the care of oral involvement in patients with systemic sclerosis.Arthritis Care Res. 2011; 63: 1126-1133
- The Modified Barium Swallow Study for Oropharyngeal Dysphagia: Recommendations From an Interdisciplinary Expert Panel.Perspectives of the ASHA Special Interest Groups. 2021; 6: 610-619
- Gastrointestinal manifestations of systemic sclerosis.Journal of Scleroderma and Related Disorders. 2016; 1: 247-256
- Weak and absent peristalsis.Neuro Gastroenterol Motil. 2012; 24: 40-47
- Comparison of simultaneous swallowing endoscopy and videofluoroscopy in neurogenic dysphagia.J Am Med Dir Assoc. 2021; 23: 1360-1366
- A prospective assessment of the characteristics of dysphagia in myasthenia gravis.Dysphagia. 2002; 17: 147-151
- Dysphagia in myositis: a study of the structural and physiologic changes resulting in disordered swallowing.Am J Phys Med Rehabil. 2020; 99: 404-408
- Oropharyngeal dysphagia.Gastroenterol Clin. 2009; 38: 411-431
- Extended myositis-specific and-associated antibodies profile in systemic sclerosis: a cross-sectional study.Joint Bone Spine. 2021; 88: 105048
- Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort.Scand J Rheumatol. 2014; 43: 217-220
- Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.Neurology. 2019; 92: e1416-e1426
- Myasthenia gravis — autoantibody characteristics and their implications for therapy.Nat Rev Neurol. 2016; 12: 259-268
- The impact of dysphagia in myositis: a systematic review and meta-analysis.J Clin Med. 2020; 9: 2150
- Gastrointestinal and hepatic disease in systemic sclerosis.Rheum Dis Clin. 2018; 44: 15-28
- Early endoscopy in systemic sclerosis without gastrointestinal symptoms.Rheumatol Int. 2012; 32: 165-168
- High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.Semin Arthritis Rheum. 2017; 47: 403-408
- Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life.Clin Gastroenterol Hepatol. 2017; 15: 207-213.e1
- High-Resolution Manometry in Clinical Practice.Gastroenterol Hepatol. 2015; 11: 374-384
- Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0.Neuro Gastroenterol Motil. 2021; 33: e14058
- Association between clinical manifestations of systemic sclerosis and esophageal dysmotility assessed by high-resolution manometry.Journal of Scleroderma and Related Disorders. 2017; 2: 50-56
- Severe oesophageal disease and its associations with systemic sclerosis.Clin Exp Rheumatol. 2017; 35: 82-85
- Multiple rapid swallowing: a complementary test during standard oesophageal manometry.Neuro Gastroenterol Motil. 2009; 21: 718-e41
- Loss of peristaltic reserve, determined by multiple rapid swallows, is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Research Support, N.I.H.Extramural. Clinical Gastroenterology & Hepatology. 2016; 14: 1502-1506
- Update of EULAR recommendations for the treatment of systemic sclerosis.Ann Rheum Dis. 2017; 76: 1327-1339
- Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis.Clin Exp Rheumatol. 2014; 32: 214-221
- Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't.Gastroenterology. 1987; 93: 311-315
- The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't.Br J Clin Pharmacol. 1991; 31: 683-687
- Metoclopramide response in patients with progressive systemic sclerosis: effect on esophageal and gastric motility abnormalities.Arch Intern Med. 1987; 147: 1597-1601
- Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Clinical Trial.Arthritis Rheum. 1977; 20: 30-34
- The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Clinical Trial.Arthritis Res Ther. 2016; 18: 195
- Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance.Curr Cardiol Rev. 2009; 5: 166-176
- Gastrointestinal dysmotility and infections in systemic sclerosis- an indian scenario. observational study.Curr Rheumatol Rev. 2018; 14: 172-176
- Gastrointestinal manifestations of systemic sclerosis.Review. Seminars in Arthritis & Rheumatism. 1994; 24: 29-39
- Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.Clin Exp Rheumatol. 2013; 31: 57-63
- ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.Journal of the American College of Gastroenterology. 2022; 117: 27-56
- Management of gastrointestinal involvement in scleroderma.Current Treatment Options in Rheumatology. 2015; 1: 82-105
Chitkara DK, Van Tilburg M, Whitehead WE, et al. Teaching diaphragmatic breathing for rumination syndrome, Journal of the American College of Gastroenterology, 101(11), 2006. 2449-2452.
- Effects of diaphragmatic breathing on the pathophysiology and treatment of upright gastroesophageal reflux: a randomized controlled trial.Journal of the American College of Gastroenterology. 2021; 116: 86-94
- Interchangeable use of proton pump inhibitors based on relative potency.Clin Gastroenterol Hepatol. Jun. 2018; 16: 800-808.e7
- Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.World J Gastroenterol. 2005; 11: 4067-4077
- Medical treatments in the short term management of reflux oesophagitis.Cochrane Database Syst Rev. 2007; : Cd003244
- Esophageal involvement and determinants of perception of esophageal symptoms among south koreans with systemic sclerosis.Journal of Neurogastroenterology and Motility. 2020; 26: 477-485
- Reflux hypersensitivity: how to approach diagnosis and management.Curr Gastroenterol Rep. 2020; 22: 42
- Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.Dis Esophagus. 2005; 18: 370-373
- Diagnosis and management of refractory gastroesophageal reflux disease.Gastroenterol Hepatol. 2021; 17: 305-315
- Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.Journal of the American College of Gastroenterology. 2006; 101: 1956-1963
- Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers.LWW, 2004: 1037-1043
- Assessment of concordance of symptom reflux association tests in ambulatory pH monitoring.Aliment Pharmacol Ther. 2012; 35: 1080-1087
- Multichannel intraluminal impedance and pH monitoring in gastroesophageal reflux disease.Expet Rev Gastroenterol Hepatol. 2008; 2: 665-672
- Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring.Am J Respir Crit Care Med. 2009; 179: 408-413
- What Is New in Rome IV.J Neurogastroenterol Motil. 2017; 23: 151-163
- Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.Journal of Scleroderma and Related Disorders. 2021; 7: 57-61
- Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.Aliment Pharmacol Ther. 2016; 43: 240-251
- Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease.Biomedical Reports. 2021; 14: 1
- Pathophysiology of gastro-oesophageal reflux disease.Acta Otorhinolaryngol Ital. 2006; 26: 241-246
- Esophageal Involvement in Scleroderma: Clinical, Endoscopic, and Manometric Features.ISRN Rheumatology. 2011; : 325826https://doi.org/10.5402/2011/325826
- Spectrum of esophageal dysmotility in systemic sclerosis on high-resolution esophageal manometry as defined by Chicago classification. Article.Dis Esophagus. 2017; 30: 1-6
- Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.World J Gastroenterol. 2014; 20: 2412-2419
- The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials.Gastroenterology Research and Practice. 2014; : 307805https://doi.org/10.1155/2014/307805
- Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.Aliment Pharmacol Ther. 2003; 17: 243-251
- Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Randomized Controlled Trial Research Support, Non-U.S. Gov't.Arthritis Res Ther. 2017; 19: 145
- Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention.Clin Exp Rheumatol. 2011; 29: S22-S25
- Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Randomized Controlled Trial Research Support, Non-U.S. Gov't.Rheumatology. 2019; 58: 1985-1990
- A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't.Semin Arthritis Rheum. 2019; 49: 411-419
- Acute colonic pseudo-obstruction.Journal of British Surgery. 2009; 96: 229-239
- Chronic intestinal pseudo-obstruction.World J Gastroenterol. 2008; 14: 2953-2961https://doi.org/10.3748/wjg.14.2953
- Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis.Dig Dis Sci. 1998; 43: 2398-2404
- Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy.Rheumatology. 2022; https://doi.org/10.1093/rheumatology/keac074
- Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Comparative Study.Scand J Rheumatol. 2003; 32: 348-355
- Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Comparative Study Support and AuthorAnonymous, Research Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Am J Gastroenterol. 1998; 93: 1085-1089
- Gastric involvement in systemic sclerosis: a prospective study. Clinical Trial Controlled Clinical Trial.Am J Gastroenterol. 2001; 96: 77-83
- Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. Clinical Trial.J Lab Clin Med. 1998; 132: 541-546
- The relationship between gastrointestinal transit, Medsger GI severity, and UCLA GIT 2.0 symptoms in patients with systemic sclerosis.Arthritis Care Res. 2020; 16: 16
- Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms.Dig Dis Sci. 2018; 63: 2231-2243
- The investigation and treatment of diabetic gastroparesis.Clin Therapeut. 2018; 40: 850-861
- American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.Gastroenterology. 2004; 127: 1592-1622
- Gastrointestinal manifestations of systemic sclerosis.Dig Dis Sci. 2008; 53: 1163-1174
- Gastroparesis.Gastroenterology. 2022; 162: 68-87.e1
- Gastrointestinal transit in patients with systemic sclerosis.Scand J Gastroenterol. 2011; 46: 1187-1193
- Gastric dysmotility after liquid bolus ingestion in systemic sclerosis: an ultrasonographic study.Rheumatol Int. 2012; 32: 1219-1223
- Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients.Scand J Gastroenterol. 1994; 29: 807-813
- Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment.Am J Gastroenterol. 1989; 84
- Mirtazapine for symptom control in refractory gastroparesis.Drug Des Dev Ther. 2017; 11: 1035-1041
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.Front Pharmacol. 2021; 12: 711500
- Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't.Endocr J. 2014; 61: 735-742
- Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.Journal of the American College of Gastroenterology. 2019; 114: 1265-1274
- Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. Research Support, N.I.H., Extramural.J Rheumatol. 2014; 41: 99-105
- Watermelon stomach in systemic sclerosis: its incidence and management.Aliment Pharmacol Ther. 2008; 28: 412-421
- Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies.Semin Arthritis Rheum. 2020; 50: 938-942
- Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors.J Rheumatol. 2010; 37: 603-607
- Current management of the gastrointestinal complications of systemic sclerosis. Review Research Support, Non-U.S. Gov't.Nat Rev Gastroenterol Hepatol. 2016; 13: 461-472
- Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide.J Rheumatol. 2009; 36: 1653-1656
- Gastric antral vascular ectasia in systemic sclerosis: complete resolution with methylprednisolone and cyclophosphamide. Case Reports Review.Annals of the Rheumatic Diseases. 2001; 60: 796-798
- Intravenous cyclophosphamide for gastric antral vascular ectasia associated with systemic sclerosis refractory to endoscopic treatment: a case report and review of the pertinent literature.Intern Med. 2019; 58: 135-139
- Gastrointestinal manifestations of progressive systemic sclerosis.Am J Gastroenterol. 1997; 92: 763-771
- Assessment of gastrointestinal involvement. Review.Clin Exp Rheumatol. 2003; 21: S15-S18
Article info
Publication history
Published online: February 28, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
